Combination Adoptive Immune Cell and Anti-CD47 Therapy and Related Compositions

Abstract

Provided are nucleic acids encoding CD47 polypeptides. In some embodiments, the nucleic acids encode a CD47 polypeptide comprising a mutant CD47 Ig-like domain that reduces binding of a therapeutic anti-CD47 binding agent to the CD47 polypeptide as compared to binding of the therapeutic anti-CD47 binding agent to a wild-type CD47 polypeptide, and where the CD47 polypeptide retains binding to SIRPα. In certain embodiments, the mutant CD47 Ig-like domain comprises a mutant BC loop. Therapeutic immune cells (e.g., CAR-T cells, etc.) comprising the nucleic acids and expressing the CD47 polypeptides on their surface are also provided, as are therapeutic methods comprising administering such cells to subjects receiving an anti-CD47 therapy, e.g., to treat cancer.

Dependencies are inferred from the claim text.